NCT05013216 — Sidney Kimmel Comprehensive Cancer Center… cancer vaccine trial
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Registry record
| Registry ID | NCT05013216 ↗ |
|---|---|
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Collaborators | Stand Up To Cancer, National Cancer Institute (NCI) |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | High Risk Cancer, Pancreatic Cancer |
| Enrollment | 37 participants (target) |
| Start date | 2022-04-11 |
| Primary completion | 2027-10-01 (est.) |
| Last registry update | 30 Jun 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05013216), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05013216?
NCT05013216 (Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Is NCT05013216 recruiting?
As of the 2026-06-30 registry update, NCT05013216 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05013216?
The lead sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Collaborators: Stand Up To Cancer, National Cancer Institute (NCI).
What condition does NCT05013216 study?
The registered conditions are High Risk Cancer, Pancreatic Cancer. Primary completion is listed as 2027-10-01 (estimated).
Are results available for NCT05013216?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05013216.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.